Promising Data on Izervay and IL-6 Inhibitors Highlight Advances in Retina Treatment
New findings presented at the American Academy of Ophthalmology meeting offer hope for patients with geographic atrophy and uveitic macular edema.
ORLANDO — Recent data unveiled at the American Academy of Ophthalmology meeting’s Retina Subspecialty Day showcase significant progress in the treatment of retinal diseases. A leading retina specialist highlighted long-term results with Izervay (avacincaptad pegol intravitreal solution, Astellas) for geographic atrophy, alongside emerging data on interleukin-6 inhibitors for uveitic macular edema.
“There were also some amazing talks on surgical innovation and of course very educational talks on the practice of medicine and tips and tricks for the busy retina specialist,” said Diana V. Do, MD, vice chair of clinical affairs and professor at Byers Eye Institute at Stanford University.
The presentation of long-term data regarding Izervay offers valuable insight into its efficacy in slowing the progression of geographic atrophy, a leading cause of vision loss in older adults. Simultaneously, the new data on interleukin-6 inhibitors signal a potential breakthrough in managing uveitic macular edema, an inflammatory condition affecting central vision.
Dr. Do’s insights underscore the dynamic nature of the field, with ongoing advancements in both pharmacological and surgical approaches. These developments promise to refine treatment strategies and improve outcomes for individuals facing these challenging retinal conditions.
Financial Disclosures
Dr. Do reports consulting for 4DMT, Adverum, Apellis Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Belite Bio, Boehringer Ingelheim, EyePoint, Genentech, Iveric Bio, Kodiak Sciences, Kriya Therapeutics, LumiThera, Regeneron and Regenxbio; receiving grant support from Belite Bio, Boehringer Ingelheim, LumiThera, Regeneron and Regenxbio; and holding stock in Belite Bio and Kodiak Sciences.
Access to Cutting-Edge Medical Information
Readers can explore additional clinical resources through Healio’s AI-powered knowledge base, including access to PubMed, information on enrolling/recruiting trials, and relevant guidelines. Furthermore, Healio provides access to Clinical Guidance, Healio CME, and the latest FDA news, alongside exclusive daily coverage of clinical data.
